Brooklyn ImmunoTherapeutics Inc. (BTX): The stock ticks all the boxes for top investors – Invest Chronicle
Home  »  News   »  Brooklyn ImmunoTherapeutics Inc. (BTX): The stock ...

Brooklyn ImmunoTherapeutics Inc. (BTX): The stock ticks all the boxes for top investors

At the end of the latest market close, Brooklyn ImmunoTherapeutics Inc. (BTX) was valued at $0.48. In that particular session, Stock kicked-off at the price of $0.4728 while reaching the peak value of $0.53 and lowest value recorded on the day was $0.4701. The stock current value is $0.52.Recently in News on June 17, 2022, Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency. Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement (“Minimum Bid Requirement”) of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. You can read further details here

Brooklyn ImmunoTherapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.9600 on 01/03/22, with the lowest value was $0.4602 for the same time period, recorded on 06/21/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Brooklyn ImmunoTherapeutics Inc. (BTX) full year performance was -96.80%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Brooklyn ImmunoTherapeutics Inc. shares are logging -97.75% during the 52-week period from high price, and 14.06% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.46 and $23.34.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 700196 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Brooklyn ImmunoTherapeutics Inc. (BTX) recorded performance in the market was -87.41%, having the revenues showcasing -75.24% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 30.74M, as it employees total of 10 workers.

Analysts verdict on Brooklyn ImmunoTherapeutics Inc. (BTX)

During the last month, 0 analysts gave the Brooklyn ImmunoTherapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.5181, with a change in the price was noted -1.96. In a similar fashion, Brooklyn ImmunoTherapeutics Inc. posted a movement of -78.83% for the period of last 100 days, recording 481,096 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Brooklyn ImmunoTherapeutics Inc. (BTX): Technical Analysis

Raw Stochastic average of Brooklyn ImmunoTherapeutics Inc. in the period of last 50 days is set at 4.97%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.33%. In the last 20 days, the company’s Stochastic %K was 11.61% and its Stochastic %D was recorded 7.21%.

Let’s take a glance in the erstwhile performances of Brooklyn ImmunoTherapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -87.41%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -89.22%, alongside a downfall of -96.80% for the period of the last 12 months. The shares increased approximately by -2.90% in the 7-day charts and went up by -26.86% in the period of the last 30 days. Common stock shares were lifted by -75.24% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]